ESC 2022: Diretriz cardio-oncologia

ESC 2022: ADVOR study evaluates the use of acetazolamide to improve congestion in patients with HF

The ADVOR study, presented at the European Congress (ESC 2022), aimed to assess whether the use of acetazolamide associated with standard therapy with intravenous loop diuretics would lead to greater success in improving congestion in patients with heart failure (HF). Read too: ESC 2022: Cardio-oncology Guideline It was a multicenter, randomized, placebo-controlled, double-blind study that …

ESC 2022: ADVOR study evaluates the use of acetazolamide to improve congestion in patients with HF Read More »